Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharma PLC (HOPHF), associated with Hemogenyx Pharmaceuticals plc (LSE: HEMO), generates news primarily around its clinical development, financing, and strategic collaboration activities in biotechnology. The company describes itself as a clinical stage biopharmaceutical group developing new medicines and treatments for blood and autoimmune diseases, with a particular focus on its HG-CT-1 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML).
News updates frequently cover milestones in the Phase I clinical trial of HG-CT-1, including first-in-human dosing, safety evaluations, early signs of efficacy, and decisions by the independent Data Safety Monitoring Board on dose escalation. Additional coverage includes regulatory developments such as FDA interactions, Institutional Review Board approvals for pediatric enrollment, and broader trial design updates for both adult and pediatric patients.
Hemogenyx Pharmaceuticals also issues announcements on operational and strategic initiatives, such as its manufacturing partnership with Made Scientific to support HG-CT-1 production and its letter of intent with Cellin Technologies in Estonia to explore commercialization under the hospital exemption pathway. Capital markets news includes publication of a prospectus, share issuances arising from warrant exercises and restricted stock units, and updates on admission of new shares to the Official List and to trading on the London Stock Exchange.
Visitors to this news page can review a stream of company disclosures that document clinical progress, financing activities, manufacturing arrangements, and potential early revenue pathways. For investors and observers interested in CAR-T therapies, hematology-oncology, and early-stage biopharmaceutical development, Hemogenyx-related news provides insight into how the company is advancing its lead program and supporting infrastructure over time.
Hemogenyx Pharmaceuticals (OTC:HOPHF) has secured £250,000 through a strategic share placement, issuing 133,690 new ordinary shares at 187p per share, representing a premium to the current market price. The shares will be initially allotted to CEO Vladislav Sandler, who will then transfer them to a group of new investors.
The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, their Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The company reports that the first two patients have completed four-week safety trials with encouraging early efficacy signs.
The deal includes one-for-one warrants exercisable at 187p for 36 months. Upon admission of the new shares, expected around August 7, 2025, the total number of issued shares will be 4,727,229.
Hemogenyx Pharmaceuticals (LSE:HEMO, OTC:HOPHF) has secured a $120,000 G-Rex® grant from ScaleReady, in partnership with Wilson Wolf Manufacturing and Cell Ready. The grant will support the optimization and scale-up of manufacturing for HG-CT-1, the company's lead CAR-T product candidate currently in Phase I trials for relapsed/refractory acute myeloid leukemia.
The funding will enable development of a closed-system, G-Rex®-based manufacturing platform, aimed at reducing production complexity, enhancing regulatory compliance, and lowering per-patient manufacturing costs. The grant includes technical consulting support in lean bioprocessing, regulatory strategy, and process engineering to support future clinical and commercial-scale manufacturing.
Hemogenyx Pharmaceuticals (LSE:HEMO) has filed an amendment to its ongoing Phase I clinical trial protocol for HG-CT-1, its CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML). The amendment seeks to expand trial eligibility to include children and adolescents, beyond the current adult patient population. This expansion aims to address a critical unmet medical need in pediatric oncology, particularly for R/R AML, which has limited treatment options and poor prognosis. The company has already treated two patients in the adult cohort of the trial.
Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £451,250 through a placing of 250,000 new ordinary shares at 180.5p per share. The shares were initially allotted to CEO Vladislav Sandler, who will direct their issue to an institution for immediate sale to an identified purchaser. The purchaser will receive one-for-one warrants exercisable for 36 months at 270 pence.
The funds will support the continuation of Phase I clinical trials for the company's HG-CT-1 therapy, targeting relapsed/refractory acute myeloid leukemia in adults. Two patients have already been infused with the treatment. Upon admission of the new shares, expected around May 14, 2025, the total number of issued shares will be 4,343,539.
Hemogenyx Pharmaceuticals (LSE: HEMO) has announced the successful treatment of a second patient in its Phase I clinical trial of HG-CT-1, a proprietary CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This milestone follows the successful first-in-human treatment, which showed a favorable initial safety profile with no adverse effects. The Phase I trial is designed as a dose-escalation study to evaluate HG-CT-1's safety profile and collect data on secondary endpoints including anti-leukemic activity, survival rates, and duration of response. The company aims to potentially expand into pediatric trials following successful initial outcomes, addressing a significant unmet medical need in childhood AML treatment.
Hemogenyx Pharmaceuticals (LSE: HEMO), a biopharmaceutical company focused on blood disease treatments, has released its final audited results for the year ending December 31, 2024. The company achieved several significant milestones including:
- Initiation of Phase I clinical trials for their HG-CT-1 product candidate
- Continued development of their Chimeric Bait Receptor antiviral/biodefence platform, which received recognition at major conferences
- Successful fundraising of £3.9 million through new ordinary shares in 2024
- Additional funding of £1.3 million secured in early 2025
The complete annual report is accessible on the company's website at hemogenyx.com.
Hemogenyx Pharmaceuticals (LSE:HEMO) has submitted its Annual Report to the FDA under the active Investigational New Drug (IND) application for HG-CT-1, their CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (R/R AML).
The report covers the first year of clinical trials through February 6, 2025, and includes:
- Study information detailing trial design, objectives, and confirmation of first patient enrollment
- Quality data on HG-CT-1 drug product stability and lentiviral vector manufacturing
- Forward-looking plans for continued patient enrollment
The submission represents a significant milestone in HG-CT-1's clinical development, demonstrating the company's progress in advancing a potential therapy for R/R AML patients.